Loading clinical trials...
Loading clinical trials...
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Vical
NCT03748069 · Influenza With Pneumonia, Invasive Pulmonary Aspergillosis
NCT06537726 · Leukemia, Leukemia, Myeloid, and more
NCT03717623 · Posaconazole, Pharmacokinetics, and more
NCT06382922 · Invasive Aspergillosis
NCT06583512 · Invasive Aspergillosis, Antifungal Therapy
University of Alabama at Birmingham Hospital, Division of Infectious Diseases
Birmingham, Alabama
UC San Diego Moores Cancer Center
La Jolla, California
UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases
Sacramento, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions